论文部分内容阅读
９６名健康育龄妇女，随机分为Ｃｙｃｌｏｆｅｍ组（复方醋酸甲孕酮）和Ｍｅｓｉｇｙｎａ组（复方庚炔诺酮），连续用针９个月，观察两针剂对抗凝血酶Ⅲ及Ｘ因子的影响，并以口服片Ｏｒｔｈｏ－Ｎｏｖｕｍ１／３５作对照。结果表明，Ｃｙｃｌｏｆｅｍ组，ＡＴ血活性变化不明显，其含量则呈现升高趋势．对Ｘ因子无明显影响。Ｍｅｓｉｇｙｎａ组，ＡＴⅢ活性略有下降．而其含量则无明显变化，同时，Ｘ因子明显下降（降低４．２％到１０．７％）．在ＯＣ组，ＡＴⅢ活性稍有下降，但不显著，其含量的基础值高于用什组（Ｐ＜０．０５），服药期间呈下降趋势，Ｘ因子则显著增加（１６．８％到２３．５％）。认为商种避孕针剂对ＡＴⅢ的影响均无重要的临床意义。
Ninety-six healthy women of childbearing age were randomly divided into Cyclofem group (Compound Medroxyprogesterone acetate) and Mesigyna group (Compound norethisterone) for 9 months. The effects of two injections on antithrombin III and X factor were observed Ortho-Novum1 / 35 oral tablets as a control. The results showed that, Cyclofem group, AT blood activity did not change significantly, its content showed an upward trend. No significant effect on the X factor. Mesigyna group, ATⅢ activity decreased slightly. While its content did not change significantly, meanwhile, factor X decreased obviously (decreased by 4.2% to 10.7%). In OC group, the activity of ATⅢ decreased slightly, but not significantly, and its basal value was higher than that of the control group (P <0.05). During the medication period, the activity of ATⅢ decreased and the factor X increased significantly (16.8% -23 .5%). That commercial contraceptives on the impact of AT Ⅲ no important clinical significance.